Amarin announces to present additional analysis from REDUCE-IT outcomes trial

Amarin (AMRN) announced that investigators will present an additional subgroup analysis from the REDUCE-IT outcomes trial in patients with and without coronary artery disease, CAD, history and mechanistic data on eicosapentaenoic acid, EPA, at the American Heart Association’s Scientific Sessions, November 16-18, 2024 in Chicago, IL. “The data to be presented at the AHA Scientific Sessions continues to affirm the clinical utility and value of VASCEPA/VAZKEPA, not only in the overall REDUCE-IT trial population, but also across various subgroups analyzed to date,” said Steve Ketchum, PhD, Chief Scientific Officer at Amarin. “Data presented at AHA will showcase new evidence from the REDUCE-IT CAD subanalysis, highlighting the benefits of VASCEPA/VAZKEPA in secondary prevention patients, with and without CAD history.”